familymednews.com
Many European countries lack a comprehensive policy to eliminate viral hepatitis as a major public health threat, according to a patient group-based survey implemented in 25 countries. The Hep-CORE study was coordinated by ISGlobal – an institution supported by the “la Caixa” Foundation – and led by the European Liver Patient’s Association. In 2016, viral hepatitis caused more deaths than […]
Continue reading »
Patients with chronic hepatitis C virus (HCV) infection who achieve a sustained virological response (SVR) after direct-acting antiviral agent (DAA) treatment have lower all-cause mortality, according to a real-world study presented today at The International Liver Congress 2018 in Paris, France. The study, conducted in Italy, found that patients who achieved SVR were at reduced risk of death from both […]
Continue reading »
A large-scale study evaluating the feasibility of decentralized care and the provision of free direct-acting antiviral agents (DAAs) has reported high rates of cure among a population of almost 20,000 individuals completing treatment for hepatitis C virus (HCV) infection. The study conducted in Punjab, India, which was reported today at The International Liver Congress 2018 in Paris, France, validated the […]
Continue reading »
Hepatitis A viruses (HAVs) circulating in an ongoing outbreak among men who have sex with men (MSM) in the Lombardy region of Italy are predominantly attributable to strains linked to two other recent outbreaks in Europe, according to a study presented today at The International Liver Congress 2018 in Paris, France. The study found that earlier cases in the Lombardy […]
Continue reading »